Selinexor

W. Riaz, N. Burke, Amit Mahipal

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Advances in the understanding of the pathophysiology, molecular biology and genetics of solid tumors and hematological malignancies have culminated in the development of novel targeted therapeutic agents leading to improved prognosis and quality of life for cancer patients. Despite these advances, prognosis remains poor for many cancer patients, and there is an unmet need for new therapeutic options. Exportin-1 (XPO1) is a nuclear export receptor that is responsible for exporting proteins, including tumor suppressor proteins, out of the nucleus. Nuclear export of tumor suppressor proteins is an important mechanism by which cancer cells avoid apoptosis and cell death. Overexpression of XPO1 imparts poor prognosis, indicating that XPO1 inhibition can be a potential therapeutic target. Recently, selective inhibitors of nuclear export (SINE) drugs have been developed. Selinexor (KPT-330) is an oral SINE with a favorable toxicity profile and demonstrated to have preclinical and clinical activity against a broad range of solid tumors and hematological malignancies.

Original languageEnglish (US)
Pages (from-to)685-692
Number of pages8
JournalDrugs of the Future
Volume39
Issue number10
DOIs
StatePublished - Oct 1 2014
Externally publishedYes

Fingerprint

Cell Nucleus Active Transport
Tumor Suppressor Proteins
Hematologic Neoplasms
Neoplasms
Molecular Biology
Cytoplasmic and Nuclear Receptors
Cell Death
Therapeutics
Quality of Life
KPT-330
Apoptosis
Pharmaceutical Preparations
Proteins

Keywords

  • Cancer
  • Exportin-1
  • KPT-330
  • Nuclear export receptor
  • Selinexor

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Selinexor. / Riaz, W.; Burke, N.; Mahipal, Amit.

In: Drugs of the Future, Vol. 39, No. 10, 01.10.2014, p. 685-692.

Research output: Contribution to journalArticle

Riaz, W, Burke, N & Mahipal, A 2014, 'Selinexor', Drugs of the Future, vol. 39, no. 10, pp. 685-692. https://doi.org/10.1358/dof.2014.039.010.2207248
Riaz, W. ; Burke, N. ; Mahipal, Amit. / Selinexor. In: Drugs of the Future. 2014 ; Vol. 39, No. 10. pp. 685-692.
@article{d53adf5246974906af58c179db421434,
title = "Selinexor",
abstract = "Advances in the understanding of the pathophysiology, molecular biology and genetics of solid tumors and hematological malignancies have culminated in the development of novel targeted therapeutic agents leading to improved prognosis and quality of life for cancer patients. Despite these advances, prognosis remains poor for many cancer patients, and there is an unmet need for new therapeutic options. Exportin-1 (XPO1) is a nuclear export receptor that is responsible for exporting proteins, including tumor suppressor proteins, out of the nucleus. Nuclear export of tumor suppressor proteins is an important mechanism by which cancer cells avoid apoptosis and cell death. Overexpression of XPO1 imparts poor prognosis, indicating that XPO1 inhibition can be a potential therapeutic target. Recently, selective inhibitors of nuclear export (SINE) drugs have been developed. Selinexor (KPT-330) is an oral SINE with a favorable toxicity profile and demonstrated to have preclinical and clinical activity against a broad range of solid tumors and hematological malignancies.",
keywords = "Cancer, Exportin-1, KPT-330, Nuclear export receptor, Selinexor",
author = "W. Riaz and N. Burke and Amit Mahipal",
year = "2014",
month = "10",
day = "1",
doi = "10.1358/dof.2014.039.010.2207248",
language = "English (US)",
volume = "39",
pages = "685--692",
journal = "Drugs of the Future",
issn = "0377-8282",
publisher = "Prous Science",
number = "10",

}

TY - JOUR

T1 - Selinexor

AU - Riaz, W.

AU - Burke, N.

AU - Mahipal, Amit

PY - 2014/10/1

Y1 - 2014/10/1

N2 - Advances in the understanding of the pathophysiology, molecular biology and genetics of solid tumors and hematological malignancies have culminated in the development of novel targeted therapeutic agents leading to improved prognosis and quality of life for cancer patients. Despite these advances, prognosis remains poor for many cancer patients, and there is an unmet need for new therapeutic options. Exportin-1 (XPO1) is a nuclear export receptor that is responsible for exporting proteins, including tumor suppressor proteins, out of the nucleus. Nuclear export of tumor suppressor proteins is an important mechanism by which cancer cells avoid apoptosis and cell death. Overexpression of XPO1 imparts poor prognosis, indicating that XPO1 inhibition can be a potential therapeutic target. Recently, selective inhibitors of nuclear export (SINE) drugs have been developed. Selinexor (KPT-330) is an oral SINE with a favorable toxicity profile and demonstrated to have preclinical and clinical activity against a broad range of solid tumors and hematological malignancies.

AB - Advances in the understanding of the pathophysiology, molecular biology and genetics of solid tumors and hematological malignancies have culminated in the development of novel targeted therapeutic agents leading to improved prognosis and quality of life for cancer patients. Despite these advances, prognosis remains poor for many cancer patients, and there is an unmet need for new therapeutic options. Exportin-1 (XPO1) is a nuclear export receptor that is responsible for exporting proteins, including tumor suppressor proteins, out of the nucleus. Nuclear export of tumor suppressor proteins is an important mechanism by which cancer cells avoid apoptosis and cell death. Overexpression of XPO1 imparts poor prognosis, indicating that XPO1 inhibition can be a potential therapeutic target. Recently, selective inhibitors of nuclear export (SINE) drugs have been developed. Selinexor (KPT-330) is an oral SINE with a favorable toxicity profile and demonstrated to have preclinical and clinical activity against a broad range of solid tumors and hematological malignancies.

KW - Cancer

KW - Exportin-1

KW - KPT-330

KW - Nuclear export receptor

KW - Selinexor

UR - http://www.scopus.com/inward/record.url?scp=84930538234&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84930538234&partnerID=8YFLogxK

U2 - 10.1358/dof.2014.039.010.2207248

DO - 10.1358/dof.2014.039.010.2207248

M3 - Article

VL - 39

SP - 685

EP - 692

JO - Drugs of the Future

JF - Drugs of the Future

SN - 0377-8282

IS - 10

ER -